Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

202 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Outcomes following front-line chemotherapy in peripheral T-cell lymphoma: 10-year experience at The Royal Marsden and The Christie Hospital.
Gleeson M, Peckitt C, Cunningham D, Gibb A, Hawkes EA, Back M, Yasar B, Foley K, Lee R, Dash J, Johnson H, O'Hara C, Wotherspoon A, Attygalle A, Menasce L, Shenjere P, Potter M, Ethell ME, Dearden C, Radford J, Chau I, Linton K. Gleeson M, et al. Among authors: dearden c. Leuk Lymphoma. 2018 Jul;59(7):1586-1595. doi: 10.1080/10428194.2017.1393671. Epub 2017 Nov 9. Leuk Lymphoma. 2018. PMID: 29119842
Pentostatin treatment of cutaneous T-cell lymphoma.
Dearden C, Matutes E, Catovsky D. Dearden C, et al. Oncology (Williston Park). 2000 Jun;14(6 Suppl 2):37-40. Oncology (Williston Park). 2000. PMID: 10887643 Free article. Clinical Trial.
Peripheral T-cell lymphomas: diagnosis and management.
Dearden CE, Foss FM. Dearden CE, et al. Hematol Oncol Clin North Am. 2003 Dec;17(6):1351-66. doi: 10.1016/s0889-8588(03)00119-9. Hematol Oncol Clin North Am. 2003. PMID: 14710889 Review.
Alemtuzumab in peripheral T-cell malignancies.
Dearden C. Dearden C. Cancer Biother Radiopharm. 2004 Aug;19(4):391-8. doi: 10.1089/cbr.2004.19.391. Cancer Biother Radiopharm. 2004. PMID: 15453953 Review.
Long-term outcomes of previously untreated myeloma patients: responses to induction chemotherapy and high-dose melphalan incorporated within a risk stratification model can help to direct the use of novel treatments.
Alvares CL, Davies FE, Horton C, Patel G, Powles R, Sirohi B, Zuha R, Gatt A, Saso R, Treleaven JG, Dearden CE, Potter MN, Ethell ME, Morgan GJ. Alvares CL, et al. Among authors: dearden ce. Br J Haematol. 2005 Jun;129(5):607-14. doi: 10.1111/j.1365-2141.2005.05514.x. Br J Haematol. 2005. PMID: 15916682 Free article.
High-grade transformation in splenic marginal zone lymphoma with circulating villous lymphocytes: the site of transformation influences response to therapy and prognosis.
Dungarwalla M, Appiah-Cubi S, Kulkarni S, Saso R, Wotherspoon A, Osuji N, Swansbury J, Cunningham DC, Catovsky D, Dearden CE, Matutes E. Dungarwalla M, et al. Among authors: dearden ce. Br J Haematol. 2008 Oct;143(1):71-4. doi: 10.1111/j.1365-2141.2008.07301.x. Epub 2008 Jul 30. Br J Haematol. 2008. PMID: 18671706 Free article.
202 results